+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor IX"

From
Hemophilia- Pipeline Insight, 2025 - Product Thumbnail Image

Hemophilia- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 250 Pages
  • Global
From
Hemophilia B - Pipeline Insight, 2025 - Product Thumbnail Image

Hemophilia B - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Hemophilia B Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Hemophilia B Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery. Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia. Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more